Volume 6 Issue 4
Jul.  2015
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2015  >  6(4): 230-234
Qiu Tao, Zhou Jiangqiao, Liu Xiuheng, et al. Comparative study of application of standard double-and single-dose of basiliximab in renal transplantation[J]. ORGAN TRANSPLANTATION, 2015, 6(4): 230-234. doi: 10.3969/j.issn.1674-7445.2015.04.005
Citation: Qiu Tao, Zhou Jiangqiao, Liu Xiuheng, et al. Comparative study of application of standard double-and single-dose of basiliximab in renal transplantation[J]. ORGAN TRANSPLANTATION, 2015, 6(4): 230-234. doi: 10.3969/j.issn.1674-7445.2015.04.005
shu

Comparative study of application of standard double-and single-dose of basiliximab in renal transplantation

doi: 10.3969/j.issn.1674-7445.2015.04.005

  • Department of Organ Transplantation, Renmin Hospital of Wuhan University, Wuhan 430060, China

More Information
  • Corresponding author: ZhouJiangqiao. Email:mdzhoujq@yahoo.com
  • Received Date: 2015-03-15
    Available Online: 2021-01-19
  • Publish Date: 2015-07-15
    Abstract
  •   Objective  To compare clinical efficacy and safety between standard double-and single-dose of basiliximab in renal transplantation.  Methods  A total of 121 patients undergoing allogeneic cadaveric renal transplantation in Department of Urology of Renmin Hopsital of Wuhan University from January 2008 to May 2011 were recruited as study subjects. Among them, 53 patients were assigned into the double-dose of basiliximab group and they were intravenously administered with 20 mg of basiliximab before and 4 d after surgery according to product description. Sixty-eight cases were allocated in the single-dose of basiliximab group and they were given with 20 mg of basiliximab before renal transplantation. The changes of immune function in two groups during perioperative period were monitored. The incidence of adverse reactions including delayed graft function (DGF), acute rejection, pulmonary infection and the survival of patients and renal grafts were statistically compared between two groups.  Results  There was no significant difference in preoperative humoral immune and cellular immune function between two groups. Compared with preoperative period, cellular and humoral immune function in both groups were inhibited by varying degree at 5 d after surgery (both in P < 0.05). Compared with patients in the single-dose group, cellular and humoral immune functions were evidently suppressed in the double-dose group (both in P < 0.05). Compared with the parameters assessed at 5 d after surgery, cellular and humoral immune functions were restored to varying degree at 15 d after surgery, whereas still significantly lower than preoperative levels (CD3, CD4, IgM and IgA). Partial parameters (CD8 and IgG) were persistently inhibited and continued to decline compared with the levels at 5 d after surgery. The incidence of DGF was 8% in the double-dose group, and 7% in the single-dose group. During 1-year follow-up, the rejection rates in the double-and single-dose groups were 13% and 12%, and the incidence of pulmonary infection was 9% and 10%. No statistical significance was noted between two groups in terms of these parameters (all in P>0.05). The 1-year survival of patients in the double-and single-dose groups was 94% and 98%, 93% and 96% for the survival of renal grafts. No statistical significance was found between two groups (both in P>0.05).  Conclusions  Both double-and single-dose of basiliximab are efficacious in renal transplantation and do not increase the incidence of adverse reaction. The 1-year survival rates of patients and renal grafts between two groups are almost equivalent. Detection of immune function during perioperative period effectively guides individualized immune induction therapy.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    Ippoliti G, Pellegrini C, Nieswandt V. Controversies about induction therapy[J]. Transplant Proc, 2011, 43(6):2450-2452. doi: 10.1016/j.transproceed.2011.06.021
    [2]
    Wagner SJ, Brennan DC. Induction therapy in renal transplant recipients:how convincing is the current evidence?[J]. Drugs, 2012, 72(5):671-683. doi: 10.2165/11631300-000000000-00000
    [3]
    Onrust SV, Wiseman LR. Basiliximab[J]. Drugs, 1999, 57(2):207-214. doi: 10.2165/00003495-199957020-00006
    [4]
    Koch M, Becker T, Lueck R, et al. Basiliximab induction therapy in kidney transplantation:benefits for long term allograft function after 10 years?[J]. Biologics, 2009, 3:51-56. https://www.ncbi.nlm.nih.gov/pubmed/19707395
    [5]
    Baquero A, Pérez J, Rizik N, et al. Basiliximab:a comparative study between the use of the recommended two doses versus a single dose in living donor kidney transplantation[J]. Transplant Proc, 2006, 38(3):909-910. doi: 10.1016/j.transproceed.2006.02.052
    [6]
    Matl I, Bachleda P, Lao M, et al. Safety and efficacy of an alternative basiliximab (simulect) regimen after renal transplantation:administration of a single 40-mg dose on the first postoperative day in patients receiving triple therapy with azathioprine[J]. Transpl Int, 2003, 16(1):45-52. doi: 10.1111/tri.2003.16.issue-1
    [7]
    Matl I, Bachleda P, Michalsky R, et al. Basiliximab can be administered safely and effectively in a single dose on day 1 postrenal transplantation in patients receiving triple therapy with azathioprine[J]. Transplant Proc, 2001, 33(7/8):3205-3206. http://www.ncbi.nlm.nih.gov/pubmed/11750375
    [8]
    Willoughby LM, Schnitzler MA, Brennan DC, et al. Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation:application of statistical approaches to reduce bias in observational comparisons[J]. Transplantation, 2009, 87(10):1520-1529. doi: 10.1097/TP.0b013e3181a484d7
    [9]
    Wang W, Yin H, Li XB, et al. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin[J]. Chin Med J, 2012, 125(6):1135-1140. https://www.researchgate.net/publication/225052761_A_retrospective_comparison_of_the_efficacy_and_safety_in_kidney_transplant_recipients_with_basiliximab_and_anti-thymocyte_globulin
    [10]
    Togashi J, Sugawara Y, Akamatsu N, et al. A single-center experience of the use of interleukin-2 receptor antagonists for various situations in liver transplant recipients[J]. Transplant Proc, 2014, 46(3):739-743. doi: 10.1016/j.transproceed.2013.11.075
    [11]
    Zhao T, Yang C, Xue Y, et al. Impact of basiliximab on the proportion of regulatory T cells and their subsets early after renal transplantation:a preliminary report[J]. Transplant Proc, 2012, 44(1):175-178. doi: 10.1016/j.transproceed.2011.11.026
    [12]
    肖序仁, 敖建华, 闵志廉, 等.肾移植受者应用舒莱的临床研究[J].中华泌尿外科杂志, 2005, 26(11):733-735. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHMN200511003.htm

    Xiao XR, Ao JH, Min ZL, et al. Clinical study of simulect in renal allograft recipients[J]. Chin J Urol, 2005, 26(11):733-735. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHMN200511003.htm
    [13]
    李健, 许亚宏, 郭瑜, 等.两种生物免疫诱导方案对肾移植受者的影响[J].器官移植, 2014, 5(5):299-303. http://www.organtranspl.com/browse/detail/qkid/32/id/193

    Li J, Xu YH, Guo Y, et al. Effect of two biological immunologic induction therapies on renal transplant recipients[J]. Organ Transplant, 2014, 5(5):299-303. http://www.organtranspl.com/browse/detail/qkid/32/id/193
    [14]
    冯小芳, 闵敏, 左富姐, 等.小剂量兔抗人胸腺细胞免疫球蛋白与抗人T细胞猪免疫球蛋白在肾移植诱导治疗中的比较[J].肾脏病与透析肾移植杂志, 2012, 21(6):530-535. http://www.cnki.com.cn/Article/CJFDTOTAL-SZBY201206007.htm

    Feng XF, Min M, Zuo FJ, et al. Comparison of low dose thymoglobulin and ALG-P in the induction therapy for kidney transplant recipients[J]. Chin J Nephrol Dial Transplant, 2012, 21(6):530-535. http://www.cnki.com.cn/Article/CJFDTOTAL-SZBY201206007.htm
    [15]
    Lo YC, Ho HC, Wu MJ, et al. Interleukin-2 receptor antagonist does not decrease biopsy-proven acute rejection among adult Chinese kidney transplant recipients[J]. Ren Fail, 2012, 34(7):856-861. doi: 10.3109/0886022X.2012.684032
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (181) PDF downloads(11) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return